Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/jbc.M304546200 on November 20, 2003

J. Biol. Chem., Vol. 279, Issue 6, 4750-4759, February 6, 2004
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
279/6/4750    most recent
M304546200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Takada, Y.
Right arrow Articles by Aggarwal, B. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Takada, Y.
Right arrow Articles by Aggarwal, B. B.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Flavopiridol Inhibits NF-{kappa}B Activation Induced by Various Carcinogens and Inflammatory Agents through Inhibition of I{kappa}B{alpha} Kinase and p65 Phosphorylation

ABROGATION OF CYCLIN D1, CYCLOOXYGENASE-2, AND MATRIX METALLOPROTEASE-9*

Yasunari Takada and Bharat B. Aggarwal{ddagger}

From the Cytokine Research Laboratory, Departments of Bioimmunotherapy, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030

Received for publication, April 30, 2003 , and in revised form, November 10, 2003.


   ABSTRACT
TOP
 ABSTRACT
INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Flavopiridol, a synthetic flavone closely related to a compound originally isolated from the stem bark of the native Indian plant Dysoxylum binectariferum, has been found to inhibit cyclin-dependent kinases, induce apoptosis, suppress inflammation, and modulate the immune response. Because several genes in which expression is altered by flavopiridol are regulated by NF-{kappa}B, we propose that this flavone must affect the activation of NF-{kappa}B. For this report, we investigated the effect of flavopiridol on NF-{kappa}B activation by various carcinogens and inflammatory agents. Flavopiridol suppressed tumor necrosis factor (TNF)-activation of NF-{kappa}B in a dose- and time-dependent manner in several cell types, with optimum inhibition occurring upon treatment of cells with 100 nM flavopiridol for 6 h. This effect was mediated through inhibition of I{kappa}B{alpha} kinase, phosphorylation, ubiquitination, and degradation of I{kappa}B{alpha} (an inhibitor of NF-{kappa}B), and suppression of phosphorylation, acylation, and nuclear translocation of the p65 subunit of NF-{kappa}B. Besides TNF, flavopiridol also suppressed NF-{kappa}B activated by a carcinogen (cigarette smoke condensate), tumor promoters (phorbol myristate acetate and okadaic acid), and an inflammatory agent (H2O2). TNF-induced NF-{kappa}B-dependent reporter gene transcription was also suppressed by this flavone. NF-{kappa}B reporter activity induced by TNF receptor 1, TNF receptor-associated death domain, TNF receptor-associated factor-2, NF-{kappa}B-inducing kinase, and I{kappa}B{alpha} kinase, were all blocked by flavopiridol but not that activated by p65. Furthermore, flavopiridol suppressed TNF-induced activation of Akt. Flavopiridol also inhibited the expression of the TNF-induced NF-{kappa}B-regulated gene products cyclin D1, cyclooxygenase-2, and matrix metalloproteinase-9. Overall, our results indicated that flavopiridol inhibits activation of NF-{kappa}B and NF-{kappa}B-regulated gene expression, which may explain the ability of flavopiridol to suppress inflammation, modulate the immune response, and regulate cell growth.


   INTRODUCTION
TOP
 ABSTRACT
 INTRODUCTION
MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Flavopiridol is a semisynthetic flavonoid closely related to a compound originally isolated from the stem bark of Dysoxylum binectariferum (also called rohitukine), a plant indigenous to India. The parent compound is identical to flavopiridol except that a methyl group replaces the chlorophenyl moiety at position 2 (1). Flavopiridol has been shown to be a potent inhibitor of cyclin-dependent kinase (CDK)1 1, CDK 2, CDK 4, and CDK 7 (2). It inhibits CDKs by competing with ATP at the nucleotide-binding site on CDKs as indicated by kinetics studies (3) and x-ray crystallography of the CDK 2-flavopiridol complex (4). The tyrosine phosphorylation of CDK 2 is also inhibited by this flavone (5). Through inhibition of CDKs, flavopiridol induces arrest of cell growth at the G1 and G2 phases of the cell cycle (2, 6). Because of its ability to suppress the growth of breast carcinoma (2), lung carcinoma (7), chronic B cell leukemia and lymphoma (8-10), multiple myeloma (11), and head and neck squamous cell carcinoma (12), flavopiridol is currently in clinical trials for the treatment of different cancers (13-15). Flavopiridol has also been shown to enhance the activity of other growth-suppressing agents, such as tumor necrosis factor (TNF), doxorubicin, and etoposide (16-21).

Research in the last few years has indicated that besides inhibiting CDK activity, the expression of anti-apoptotic proteins, such as Bcl-2 (8), Mcl-1 (11, 22, 23), cyclin D1 (19, 24), and vascular endothelial growth factor (25, 26) has been shown to be suppressed by flavopiridol. All of the genes for these proteins are known to be regulated by the nuclear transcription factor NF-{kappa}B (27-33). Flavopiridol has also been shown to suppress inflammation and regulate the immune system (9), and again, NF-{kappa}B has been shown to control the expression of immunosuppressive and anti-inflammatory molecules (34).

These lines of evidence indicated that flavopiridol may regulate the activity of NF-{kappa}B. Thus in the present report we investigated the effect of flavopiridol on NF-{kappa}B activation induced by various carcinogens, inflammatory agents, and immune modulators. We also investigated the mechanism by which flavopiridol suppress NF-{kappa}B activation, and we found this inhibition was mediated through the suppression of Akt-induced I{kappa}B{alpha} kinase activation. Flavopiridol also suppressed the induced NF-{kappa}B-regulated gene products such as COX-2, cyclin D1, and MMP-9.


   MATERIALS AND METHODS
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
RESULTS
 DISCUSSION
 REFERENCES
 
Reagents—Flavopiridol was obtained from the Drug Synthesis and Chemistry Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, NCI, National Institutes of Health (Bethesda, MD). A 1 mM solution of flavopiridol was prepared in dimethyl sulfoxide (Me2SO) and then diluted in the cell culture medium. Bacteria-derived human recombinant TNF, purified to homogeneity with a specific activity of 5 x 107 units/mg, was kindly provided by Genentech (South San Francisco, CA). Penicillin, streptomycin, RPMI 1640 medium, Dulbecco's modified Eagle's medium, and fetal bovine serum were obtained from Invitrogen. Phorbol 12-myristate 13-acetate (PMA), okadaic acid, and H2O2 were obtained from Sigma. Cigarette smoke condensate was kindly provided by Dr. C. Gary Gariola (Toxicology Research Institute of the University of Kentucky, Lexington). The antibodies anti-p65, anti-p50, anti-I{kappa}B{alpha}, anti-cyclin D1, anti-poly(ADP)ribose polymerase (PARP), and anti-Akt antibodies were obtained from Santa Cruz Biotechnology (Santa Cruz, CA). Phosphospecific anti-I{kappa}B{alpha} (Ser-32), phosphospecific anti-Akt, and anti-acetyllysine antibodies were purchased from Cell Signaling (Beverly, MA). Anti-IKK-{alpha} and anti-IKK-{beta} antibodies were kindly provided by Imgenex (San Diego, CA). The antibody that recognizes the serine 529-phosphorylated form of p65 was obtained from Rockland Laboratories (Gilbertsville, PA).

Cell Lines—We used Jurkat (human T-cell cell line), A293 (human kidney cell line), and HL60 (human myeloid leukemia) cells, and all cells were obtained from American Type Culture Collection. Jurkat and HL60 cells were cultured in RPMI 1640 medium; A293 cells were cultured in Dulbecco's modified Eagle's medium. Both media were supplemented with 10% fetal bovine serum, 100 units/ml penicillin, and 100 µg/ml streptomycin.

Electrophoretic Mobility Shift Assays (EMSA)—To measure NF-{kappa}B activation, we performed EMSA as described (35). Briefly, nuclear extracts prepared from TNF-treated cells (2 x 106/ml) were incubated with 32P end-labeled 45-mer double-stranded NF-{kappa}B oligonucleotide (10 µg of protein with 16 fmol of DNA) from the human immunodeficiency virus long terminal repeat, 5'-TTGTTACAAGGGACTTTCCGCTGGGGACTTTCCAGGGAGGCGTGG-3' (boldface indicates NF-{kappa}B binding sites), for 30 min at 37 °C, and the DNA-protein complex formed was separated from free oligonucleotide on 6.6% native polyacrylamide gels. A double-stranded mutated oligonucleotide, 5'-TTGTTACAACTCACTTTCCGCTGCTCACTTTC CAGGGAGGCGTGG-3', was used to examine the specificity of the binding of NF-{kappa}B to the DNA. The specificity of binding was also examined by competition with the unlabeled oligonucleotide. For supershift assays, nuclear extracts prepared from TNF-treated cells were incubated with antibodies against either the p50 or p65 subunits of NF-{kappa}B for 30 min at 37 °C before the complex was analyzed by EMSA. Antibodies against cyclin D1 and preimmune serum were included as negative controls. The dried gels were visualized, and the radioactive bands were quantitated by a PhosphorImager (Amersham Biosciences) using Imagequant software.

Western Blot Analysis—To determine the levels of protein expression in cytoplasm or nuclear extracts, we prepared each extract (36) from TNF-treated cells and fractionated it by SDS-PAGE. After electrophoresis, the proteins were electrotransferred to nitrocellulose membranes, blotted with each antibody, and detected by ECL reagent (Amersham Biosciences). The density of the bands was measured using NIH Image.

I{kappa}B{alpha} Kinase Assay—The IKK assay was performed by a method described previously (37). Briefly, the IKK complex from whole-cell extracts was precipitated with antibody against IKK-{alpha}, followed by treatment with protein A/G-Sepharose beads (Pierce). After a 2 h incubation, the beads were washed with lysis buffer and then assayed in kinase assay mixture containing 50 mM HEPES (pH 7.4), 20 mM MgCl2, 2 mM dithiothreitol, 20 µCi of [{gamma}-32P]ATP, 10 µM unlabeled ATP, and 2 µg of substrate glutathione S-transferase-I{kappa}B{alpha} (1-54). After the immunocomplex was incubated at 30 °C for 30 min, it was boiled with SDS sample buffer for 5 min. Finally, the protein was resolved on 10% SDS-PAGE, the gel was dried, and the radioactive bands were visualized by PhosphorImager. To determine the total amounts of IKK-{alpha} and -{beta} in each sample, the IKK immunoprecipitate was resolved on 7.5% SDS-PAGE, electrotransferred to a nitrocellulose membrane, and then blotted with either anti-IKK-{alpha} or anti-IKK-{beta} antibodies.

Nuclear Localization of p65 NF-{kappa}B by Immunocytochemistry—The nuclear translocation of the p65 subunit of NF-{kappa}B was examined by an immunocytochemical method as described previously (38). Briefly, treated cells were plated on a poly-L-lysine-coated glass slide by centrifugation using a cytospin 4 (Thermoshendon, Pittsburg, PA), air dried, fixed with cold acetone, and permeabilized with 0.2% Triton X-100. After being washed in phosphate-buffered saline, the slides were blocked with 5% normal goat serum for 1 h and then incubated with rabbit polyclonal anti-human p65 or I{kappa}B{alpha} antibodies at 1:100 dilutions. After overnight incubation at 4 °C the slides were washed, incubated with goat anti-rabbit IgG-Alexa 594 (Molecular Probe, Eugene, OR) at 1:100 dilutions for 1 h, and counter-stained for nuclei with Hoechst 33342 (50 ng/ml) for 5 min. Stained slides were mounted with mounting medium purchased from Sigma and analyzed under a fluorescence microscope (Labophot-2, Nikon, Tokyo, Japan). Pictures were captured using Photometrics Coolsnap CF color camera (Nikon, Lewisville, TX) and MetaMorph version 4.6.5 software (Universal Imaging, Downingtown, PA).

Secretory Alkaline Phosphatase (SEAP) Assay—The effect of flavopiridol on TNF-, TNFR 1-, TRADD-, TRAF 2-, NIK-, IKK- and p65-induced NF-{kappa}B-dependent reporter gene transcription was analyzed by SEAP assay as described previously (37). To examine TNF-induced reporter gene expression, A293 cells (0.5 million cells/well) were plated in 6-well plates and transiently transfected by the calcium phosphate method with pNF-{kappa}B-SEAP (0.5 µg) and the control plasmid pCMVFLAG1 DNA (2 µg). After 24 h, cells were washed and then treated with 100 nM flavopiridol for 8 h. Cells were then exposed to 1 nM TNF for 24 h, harvested from the cell culture medium, and analyzed for SEAP activity according to the protocol essentially as described by the manufacturer (Clontech, Palo Alto, CA), using a 96-well fluorescence plate reader (Fluoroscan II, Labsystems, Chicago, IL) with excitation set at 360 nm and emission at 460 nm.

To examine TNFR 1-, TRADD-, TRAF 2-, NIK-, IKK- and p65-induced NF-{kappa}B-dependent reporter gene transcription, cells (0.5 million cells/well) were plated in six-well plates and transiently transfected by the calcium phosphate method with pNF-{kappa}B-SEAP (0.5 µg), the inducer plasmid (1 µg), and the control plasmid pCMVFLAG1 (1 µg) DNA. After 24 h, cells were washed and then treated with 100 nM flavopiridol. After 32 h, the cell culture medium was harvested and analyzed for SEAP activity as described above.


   RESULTS
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
DISCUSSION
 REFERENCES
 
In the present study, we investigated the effect of flavopiridol on NF-{kappa}B activation induced by various carcinogens and inflammatory stimuli including PMA, okadaic acid, H2O2, cigarette smoke condensate, and TNF. The effect of flavopiridol on the TNF-induced NF-{kappa}B activation was studied in detail, because the pathway has been well characterized. The structure of flavopiridol, (-)-cis-5,7-dihydroxy-2-(2-chlorphenyl)-8-[4-(3-hydroxy-1-methyl)piperidinyl]-4H-1-benzopyran-4-on, is shown in Fig. 1. The concentration of flavone, the NF-{kappa}B activators used, and the time of exposure had minimal effect on the viability of these cells (data not shown).



View larger version (18K):
[in this window]
[in a new window]
  		FIG. 1.
The structure of flavopiridol.

 
Flavopiridol Inhibits TNF-dependent NF-{kappa}B Activation—To determine the effect of flavopiridol on NF-{kappa}B activation, Jurkat, A293, and HL60 cells were incubated for 8 h with different concentrations of flavopiridol followed by 0.1 nM TNF for 30 min. Then nuclear extracts were prepared and analyzed for NF-{kappa}B activation by EMSA. As shown in Fig. 2, Flavopiridol by itself did not induce NF-{kappa}B activation but rather inhibited TNF-mediated NF-{kappa}B activation in a dose-dependent manner in all cell lines. Treatment with 150 nM flavopiridol suppressed TNF-induced NF-{kappa}B activation by almost 100% in all cell lines. During all subsequent experiments, we used HL60 cells and employed 150 nM flavopiridol.



View larger version (58K):
[in this window]
[in a new window]
  		FIG. 2.
Effect of flavopiridol on TNF-induced NF-{kappa}B activation. Dose response of flavopiridol for the inhibition of TNF-induced NF-{kappa}B activation. Cells were preincubated at 37 °C for 8 h with different concentrations of flavopiridol, followed by a 30-min incubation with 0.1 nM TNF. After these treatments, nuclear extracts were prepared and then assayed for NF-{kappa}B activation by EMSA as described under "Materials and Methods." HL60 cell viability, as determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, was 100 ± 7, 101 ± 8, 102 ± 7, 98 ± 6, 95 ± 7, 93 ± 7, 101 ± 8, 102 ± 6, 100 ± 9, 99 ± 8, 95 ± 9, and 92 ± 8%, respectively, for treatments.

 
We next tested the length of incubation required for flavopiridol to suppress TNF-induced NF-{kappa}B activation. Cells were incubated with the flavone for different times before treatment with TNF for 30 min. TNF-induced NF-{kappa}B activation was inhibited by flavopiridol in a time-dependent manner (Fig. 3A). When we incubated cells with flavopiridol for 6 h, NF-{kappa}B activation by TNF was completely inhibited.



View larger version (67K):
[in this window]
[in a new window]
  		FIG. 3.
Time-dependent inhibition of TNF-induced NF-{kappa}B activation by flavopiridol. A, HL60 cells (2 x 106 cells/ml) were preincubated at 37 °C with 150 nM flavopiridol for the indicated times and then treated with TNF at a concentration of 0.1 nM at 37 °C for 30 min. After treatment, nuclear extracts were prepared and then assayed for NF-{kappa}B activation by EMSA. B, effect of flavopiridol on the activation of NF-{kappa}B induced by different concentrations of TNF. HL60 cells (2 x 106 cells/ml) were incubated with 150 nM flavopiridol for 8 h and then treated with different concentrations of TNF at 37 °C for 30 min. Nuclear extracts were prepared and then assayed for NF-{kappa}B activation by EMSA. C, NF-{kappa}B induced by TNF is composed of p65 and p50 subunits. Nuclear extracts were prepared from untreated or 0.1 nM TNF-treated cells, incubated for 30 min with different antibodies or unlabeled NF-{kappa}B oligonucleotide probes, and then assayed for NF-{kappa}B activation by EMSA. D, effect of flavopiridol on binding of the NF-{kappa}B complex to the DNA. Nuclear extracts were prepared from untreated or 0.1 nM TNF-treated cells, incubated for 30 min with the indicated concentration of flavopiridol, and assayed for NF-{kappa}B activation by EMSA.

 
Previous studies from our laboratory have shown that 10 nM TNF can activate NF-{kappa}B within 5 min and that this induction is higher in its intensity than that obtained with cells using 100-fold lower concentrations of TNF for longer times (39). To determine the effect of flavopiridol on NF-{kappa}B activation at high concentrations of TNF, cells were pretreated with flavopiridol, exposed to various concentrations of TNF for 30 min, and analyzed for NF-{kappa}B activation by EMSA (Fig. 3B). NF-{kappa}B activated by 10 nM TNF was completely suppressed by flavopiridol; the latter alone did not activate NF-{kappa}B. These results showed that flavopiridol is a very potent inhibitor of TNF-induced NF-{kappa}B activation.

Because NF-{kappa}B is a complex of proteins, various combinations of Rel/NF-{kappa}B protein can constitute an active NF-{kappa}B heterodimer that binds to a specific sequence in DNA (40). To show that the retarded band visualized by EMSA in TNF-treated cells was indeed NF-{kappa}B, we incubated nuclear extracts from TNF-stimulated cells with antibodies to either the p50 (NF-{kappa}B1) or the p65 (RelA) subunit of NF-{kappa}B. Both shifted the band to a higher molecular mass (Fig. 3C) thus suggesting that the TNF-activated complex consisted of p50 and p65 subunits. Neither preimmune serum nor antibody against anti-cyclin D1 had any effect. Excess unlabeled NF-{kappa}B (100-fold) caused complete disappearance of the band, and a mutant oligonucleotide of NF-{kappa}B did not affect NF-{kappa}B binding activity.

To determine whether flavopiridol directly modifies the NF-{kappa}B complex, we incubated nuclear extracts from TNF-treated cells with various concentrations of flavopiridol and then analyzed for DNA binding activity by EMSA. Our results, in Fig. 3D, show that flavopiridol did not modify the DNA binding ability of NF-{kappa}B complex. Therefore, flavopiridol inhibits NF-{kappa}B activation not by preventing DNA binding directly but by an indirect mechanism.

Flavopiridol Inhibits TNF-dependent I{kappa}B{alpha} Phosphorylation—The activation of NF-{kappa}B is known to require the phosphorylation and degradation of I{kappa}B{alpha}, the natural inhibitor of NF-{kappa}B (40). To determine whether inhibition of TNF-induced NF-{kappa}B activation was because of inhibition of I{kappa}B{alpha} degradation, we pretreated cells with flavopiridol for 8 h and then exposed them to 0.1 nM TNF for the indicated times. Then we examined the cells for NF-{kappa}B activation in the nucleus by EMSA and for I{kappa}B{alpha} status in the cytoplasm by Western blot analysis. TNF-induced activation of NF-{kappa}B increased with time but did not occur at all in flavopiridol-pretreated cells even after up to 60 min of TNF stimulation (Fig. 4A). TNF induced I{kappa}B{alpha} degradation in control cells as early as 10 min, but in flavopiridol-pretreated cells, TNF failed to induce degradation of I{kappa}B{alpha} (Fig. 4B). These results indicate that flavopiridol inhibits both TNF-induced NF-{kappa}B activation and I{kappa}B{alpha} degradation.



View larger version (46K):
[in this window]
[in a new window]
  		FIG. 4.
Effect of flavopiridol on the kinetics of activation of NF-{kappa}B by TNF. A, TNF-induced time-dependent activation of NF-{kappa}B. Cells (2 x 106 cells/ml) were incubated with 150 nM flavopiridol for 8 h, treated with 0.1 nM TNF at 37 °C for the indicated times, and then analyzed for NF-{kappa}B activation by EMSA. B, effect of flavopiridol on TNF-induced degradation of I{kappa}B{alpha}. Cells (2 x 106 cells/ml) were incubated with 150 nM flavopiridol for 8 h and treated with 0.1 nM TNF at 37 °C for indicated times. Cytoplasmic extracts were prepared, fractionated on 10% SDS-PAGE, and electrotransferred to nitrocellulose membranes. Western blot analysis was performed using anti-I{kappa}B{alpha} antibody. The loading control was blotted with anti-{beta}-actin antibody. C, effect of flavopiridol on the phosphorylation of I{kappa}B{alpha} by TNF. Cells (2 x 106 cells/ml) were pretreated with 100 µg/ml ALLN for 1 h followed by 150 nM flavopiridol for 8 h and treated with 0.1 nM TNF for the indicated times. Cytoplasmic extracts were fractionated, and then Western blot analysis was performed using anti-I{kappa}B{alpha} antibody. D, effect of flavopiridol on TNF-induced ubiquitination of I{kappa}B{alpha}. Cells (2 x 106 cells/ml) were pretreated with 100 µg/ml ALLN for 1 h and then treated with 150 nM flavopiridol for 8 h before exposure to 0.1 nM TNF for 30 min. Whole-cell extracts were prepared, fractionated, and analyzed by Western blot analysis using an anti-I{kappa}B{alpha} antibody.

 
To determine whether flavopiridol affects TNF-induced I{kappa}B{alpha} phosphorylation, we examined the TNF-induced phosphorylated form of I{kappa}B{alpha} by Western blot analysis using an antibody that is specific for the serine-phosphorylated form of I{kappa}B{alpha}. Because TNF-induced phosphorylation of I{kappa}B{alpha} leads to its rapid degradation (40), we blocked phosphorylation and degradation of I{kappa}B{alpha} using the proteasome inhibitor N-Ac-Leu-Leu-norleucinal (ALLN) (41). TNF alone slightly induced phosphorylation of I{kappa}B{alpha}, but when cells were pretreated with the inhibitor, TNF-induced phosphorylation of I{kappa}B{alpha} was more pronounced (Fig. 4C). Flavopiridol almost completely suppressed the I{kappa}B{alpha} phosphorylation induced by TNF, even in the presence of the proteasome inhibitor.

Phosphorylation of I{kappa}B{alpha} by TNF leads to ubiquitination and degradation of I{kappa}B{alpha} (40). To investigate whether flavopiridol affects TNF-induced I{kappa}B{alpha} ubiquitination, we performed Western blot analysis. We used proteasome inhibitor ALLN to block the degradation of I{kappa}B{alpha} (41). TNF treatment alone slightly induced ubiquitination of I{kappa}B{alpha}, but when cells were pretreated with ALLN, TNF-induced ubiquitination of I{kappa}B{alpha} was enhanced (Fig. 4D). Flavopiridol almost completely suppressed the I{kappa}B{alpha} ubiquitination induced by TNF, even in the presence of the proteasome inhibitor.

Flavopiridol Inhibits TNF-induced IKK Activation—It has been shown that IKK is required for TNF-induced phosphorylation of I{kappa}B{alpha} (40). Because flavopiridol inhibits the phosphorylation of I{kappa}B{alpha}, we determined the effect of flavopiridol on TNF-induced IKK activation. As shown in Fig. 5A, in immune complex kinase assays TNF activated IKK as early as 2 min after TNF treatment. Flavopiridol treatment completely suppressed the TNF-induced activation of IKK. Neither TNF nor flavopiridol had any effect on the expression of IKK-{alpha} or -{beta} proteins.



View larger version (52K):
[in this window]
[in a new window]
  		FIG. 5.
Effect of flavopiridol on the TNF-induced activation of IKK and Akt. A, cells (2 x 106 cells/ml) were pretreated with 100 µg/ml ALLN for 1 h followed by 150 nM flavopiridol for 8 h and then activated with 1 nM TNF for the indicated times. Whole-cell extracts were prepared and immunoprecipitated with antibody against IKK-{alpha}. Thereafter immunocomplex kinase assay was performed as described under "Materials and Methods." To examine the effect of flavopiridol on the level of expression of IKK proteins, IKK immunoprecipitates were fractionated on 7.5% SDS-PAGE and then immunoblotted using anti-IKK-{alpha} and anti-IKK-{beta} antibodies. B, direct effect of flavopiridol on the TNF-induced activation of IKK. Cells were treated with 100 µg/ml ALLN for 1 h and then treated with 1 nM TNF for 10 min. Whole-cell extracts were prepared and immunoprecipitated with antibody against IKK-{alpha}. Thereafter immunocomplex kinase assays were performed in the absence or presence of the indicated concentrations of flavopiridol for 30 min at 30 °C. C, effect of flavopiridol on TNF-induced Akt activation. Cells (1 x 106/ml) were incubated with either medium or 150 nM flavopiridol for 8 h and then treated with 1 nM TNF for the indicated times. Whole-cell extracts were prepared and analyzed by Western blot analysis using phospho-specific anti-Akt and anti-Akt antibodies.

 
To evaluate whether flavopiridol directly interacts with IKK proteins, we incubated cytoplasmic extracts from TNF-treated cells with various concentrations of flavopiridol and then performed the kinase assay. The results in Fig. 5B show that flavopiridol did not directly affect the activity of IKK, suggesting that flavopiridol inhibits TNF-induced IKK activity through an indirect mechanism.

Flavopiridol Inhibits TNF-induced Akt Activation—Our results until now indicated that flavopiridol inhibits TNF-induced NF-{kappa}B activation through inhibition of IKK activation. However, we show that flavopiridol does not directly inhibit IKK. It is possible that this inhibition is because of inhibition of an upstream kinase. Previous studies (42) have reported that Akt can associate with and activate IKK-{alpha}. Thus it is possible that flavopiridol suppresses TNF-induced Akt activation. To determine the effect of flavopiridol on the activation of Akt induced by TNF, we treated the cells with flavopiridol (150 nM) for 8 h and then exposed the cells to TNF (1 nM) for different times. Thereafter whole-cell extracts were prepared, and we performed Western blot analysis using phosphospecific anti-Akt antibody. Results showed that TNF induced Akt activation in a time-dependent manner (Fig. 5C), and pretreatment with flavopiridol completely suppressed the activation. Thus these results indicate that flavopiridol inhibits IKK activation through suppression of Akt.

Flavopiridol Inhibits TNF-induced Nuclear Translocation of p65—TNF induces the phosphorylation of p65, which is required for NF-{kappa}B transcriptional activity. The phosphorylation of the p65 subunit is known to be mediated through IKK (43). Western blot analysis showed that TNF induced the phosphorylation of the cytoplasmic pool of p65 in a time-dependent manner, and p65 phosphorylation could be seen as early as 5 min and increased up to 30 min (Fig. 6A). Pretreatment with flavopiridol abolished the TNF-induced phosphorylation of cytoplasmic p65. Flavopiridol blocked TNF-induced translocation of p65 to the nucleus almost completely (Fig. 6B).



View larger version (47K):
[in this window]
[in a new window]
  		FIG. 6.
Effect of flavopiridol on the phosphorylation and translocation of p65 in cytoplasm and nuclei induced by TNF. A, Western blot analysis was performed using TNF-treated cytoplasmic extract. Cells (2 x 106 cells/ml) were incubated with 150 nM flavopiridol for 8 h and treated with 0.1 nM TNF for the indicated times. Cytoplasmic extracts (CE) were prepared and analyzed by Western blot analysis using phosphospecific anti-p65, anti-p65, or anti-{beta}-actin (loading control) antibodies. B, Western blot analysis was performed using nuclear extract (NE). Cells (2 x 106 cells/ml) were incubated with 150 nM flavopiridol for 8 h and treated with 0.1 nM TNF for the indicated times. Nuclear extracts were prepared and analyzed by Western blot analysis using phosphospecific anti-p65, anti-p65, or anti-poly(ADP)ribose polymerase (PARP) (loading control) antibodies. C, effect of flavopiridol on TNF-induced acetylation of p65. Cells (1 x 107 cells) were incubated with 150 nM flavopiridol for 8 h and then treated with 1 nM TNF for the indicated times. Whole-cell extracts were prepared, immunoprecipitated (IP) with anti-p65 antibody, and Western blotted (WB) using anti-acetyllysine antibody. D, immunocytochemical analysis of p65 localization after treatment with TNF in the absence or presence of flavopiridol. Cells were incubated for 8 h with 150 nM flavopiridol at 37 °C and then treated with 0.1 nM TNF. Cells were subjected to immunocytochemistry as described under "Materials and Methods."

 
The acetylation of p65 plays a key role in I{kappa}B{alpha}-mediated activation of NF-{kappa}B transcriptional activity (44). To examine the effect of flavopiridol on the acetylation of p65 by TNF, cells were pretreated with flavopiridol for 8 h and then exposed to TNF for the indicated times. Whole-cell extracts were prepared and immunoprecipitated with anti-p65 antibody, and Western blot analysis was performed using anti-acetyllysine antibody. Results showed that TNF induced acetylation of p65 in a time-dependent manner, and flavopiridol completely suppressed the TNF-induced acetylation of p65 (Fig. 6C).

As further confirmation of these results, immunocytochemistry showed that p65 localized in the cytoplasm of untreated cells. It was found to be translocated to the nucleus when treated with TNF, but pre-treatment with flavopiridol clearly suppressed this TNF-induced translocation (Fig. 6D).

Flavopiridol Blocks NF-{kappa}B Activation Induced by PMA, Okadaic Acid, H2O2, and Cigarette Smoke Condensate—Previous studies have shown that PMA, okadaic acid, H2O2, and cigarette smoke condensate are potent activators of NF-{kappa}B (45-47). However, they activate NF-{kappa}B through a pathway with overlapping and non-overlapping steps. We therefore examined the effect of flavopiridol on the activation of NF-{kappa}B by these agents. As shown in Fig. 7, flavopiridol suppressed the activation of NF-{kappa}B induced by all of these agents, suggesting that flavopiridol acts at a step in the NF-{kappa}B activation pathway that is common to the activity of all of these agents.



View larger version (105K):
[in this window]
[in a new window]
  		FIG. 7.
Effect of flavopiridol on different activators. Cells (2 x 106 cells/ml) were pre-incubated for 8 h at 37 °C with flavopiridol at a concentration of 150 nM. Cells were treated with 0.1 nM TNF for 30 min, 10 ng/ml PMA, 500 nM okadaic acid (OA), 250 µM H2O2, or 1 µg/ml cigarette smoke condensate (CSC) for 60 min and then analyzed for NF-{kappa}B activation as described under "Materials and Methods."

 
Flavopiridol Represses TNF-induced NF-{kappa}B-dependent Reporter Gene Expression—Although we have shown that flavopiridol blocks the DNA binding step in NF-{kappa}B activation, DNA binding alone does not always correlate with NF-{kappa}B-dependent gene transcription, suggesting that there are additional regulatory steps (48). To determine the effect of flavopiridol on TNF-induced NF-{kappa}B-dependent reporter gene expression, we transiently transfected the cells with the NF-{kappa}B-regulated SEAP reporter construct, incubated them with flavopiridol, and then stimulated the cells with TNF. An almost 4.5-fold increase in SEAP activity over the vector control was observed upon stimulation with 1 nM TNF (Fig. 8A). Flavopiridol repressed NF-{kappa}B-dependent reporter gene expression induced by TNF.



View larger version (37K):
[in this window]
[in a new window]
  		FIG. 8.
Flavopiridol inhibits the expression of NF-{kappa}B-dependent gene by TNF. A, flavopiridol inhibits the NF-{kappa}B-dependent reporter gene expression induced by TNF, TNFR 1, TRADD, TRAF 2, NIK, IKK, and p65. A293 cells were transiently transfected with a NF-{kappa}B-containing reporter plasmid along with indicated plasmids or TNF. Cells were pretreated with 100 nM flavopiridol for 8 h and then exposed to either 1 nM TNF or the TNF signaling pathway plasmids. After 24 h, cultured medium was harvested and assayed for SEAP activity as described under "Materials and Methods." Results are expressed as -fold activity over that in the vector control. B, flavopiridol inhibits TNF-induced cyclin D1, COX-2, and MMP-9 expression. Cells (5 x 105 cells/ml) were incubated with 100 nM flavopiridol for 8 h and then treated with 1 nM TNF for the indicated times. Whole-cell extracts were prepared and analyzed by Western blot analysis using antibodies against cyclin D1, COX-2, and MMP-9.

 
TNF-induced NF-{kappa}B activation is mediated through sequential interaction of the TNF receptor with TNFR 1, TRADD, TRAF 2, NIK, and IKK resulting in phosphorylation of I{kappa}B{alpha} (49, 50). To delineate the site of action of flavopiridol in the TNF-signaling pathway leading to NF-{kappa}B activation, cells were transfected with TNFR 1-, TRADD-, TRAF 2-, NIK-, IKK-, and p65-expressing plasmids and then NF-{kappa}B-dependent SEAP expression was monitored. As shown in Fig. 8A, cells transfected with TNFR 1-, TRADD-, TRAF 2-, NIK-, IKK-, and p65-expressing plasmids induced NF-{kappa}B-dependent expression of SEAP. Pretreatment with flavopiridol suppressed TNFR 1-, TRADD-, TRAF 2-, NIK- and IKK-induced but not p65-induced NF-{kappa}B reporter gene expression. These results suggest that flavopiridol affects a step downstream from IKK and upstream from p65.

Because TNF treatment induces cyclin D1, COX-2, and MMP-9, which have NF-{kappa}B binding sites in their promoters (31, 32, 51, 52), we next examined whether flavopiridol inhibits TNF-induced cyclin D1, COX-2, and MMP-9. Cells were pretreated with flavopiridol for 8 h and then treated with TNF for the indicated times, and whole-cell extracts were prepared and analyzed by Western blot analysis for the expression of cyclin D1, COX-2, and MMP-9 (Fig. 8B). TNF induced cyclin D1, COX-2, and MMP-9 expressions in a time-dependent manner, and flavopiridol blocked TNF-induced expression of these gene products. These results further strengthened our hypothesis that flavopiridol blocks NF-{kappa}B activation activated by a variety of inflammatory stimuli and carcinogens.


   DISCUSSION
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
REFERENCES
 
The apoptotic, anti-inflammatory, and immunomodulatory effects of flavopiridol and the associated gene expression pattern suggested that flavopiridol likely suppresses NF-{kappa}B activation. In the present report we demonstrate that flavopiridol does indeed inhibit NF-{kappa}B activated by a variety of agents and in a variety of cell lines. The inhibition of NF-{kappa}B activity was found to be because of suppression of Akt-induced IKK activation, thus resulting in inhibition of I{kappa}B{alpha} phosphorylation, ubiquitination, and degradation. Consequently, flavopiridol also blocked the p65 phosphorylation and acetylation, p65 nuclear translocation, and NF-{kappa}B-dependent reporter gene transcription. Furthermore flavopiridol suppressed NF-{kappa}B activation induced by TNFR 1, TRADD, TRAF 2, NIK, and IKK but not that induced by p65. Flavopiridol also inhibited the TNF-induced expression of cyclin D1, COX-2, and MMP-9 proteins, all of which have a NF-{kappa}B binding site in their promoters, and regulated their transcription.

Our results here indicate that flavopiridol strongly inhibits NF-{kappa}B activation. Because NF-{kappa}B activation induced by highly diverse stimuli, including TNF, PMA, H2O2, okadaic acid, and cigarette smoke condensate, was inhibited, flavopiridol must suppress activation at a step common to all of these activators. For most of these stimuli, NF-{kappa}B activation requires sequential phosphorylation at serines 32 and 36 of I{kappa}B{alpha}. I{kappa}B{alpha} undergoes phosphorylation by activation of a kinase complex consisting of IKK-{alpha} and -{beta} (53, 54), which leads to ubiquitination at lysines 21 and 22 and degradation of I{kappa}B{alpha} (55). Because flavopiridol blocked this entire cascade, it must act upstream of I{kappa}B{alpha} phosphorylation. TNF-induced NF-{kappa}B activation involves the sequential interaction of the TNF receptor with TRADD, TRAF 2, and NIK, which then activates IKK (49, 50). We found that flavopiridol inhibited NF-{kappa}B-dependent reporter gene expression induced by TNFR 1, TRADD, TRAF 2, NIK, and IKK, but not by p65, which also suggests that flavopiridol acts at a step downstream from IKK and upstream from p65.

In the present studies, we also found that flavopiridol inhibited TNF-induced activation of IKK. The antibody that specifically detected the phosphorylated form of I{kappa}B{alpha} showed that flavopiridol blocked TNF-induced phosphorylation of I{kappa}B{alpha}. Although the phosphorylation of I{kappa}B{alpha} is regulated by IKK (consisting of IKK-{alpha}, -{beta}, and -{gamma}), a large number of kinases regulate IKK, including NIK, TAK 1, Akt, and MEKK 1 (40, 46). Akt and NIK are primarily known to activate IKK-{alpha}, whereas MEKK 1 and atypical protein kinase C activate IKK-{beta}. Flavopiridol inhibited IKK activity without directly interfering with the IKK protein, thereby blocking I{kappa}B{alpha} phosphorylation, ubiquitination, and degradation. Thus it may be possible that flavopiridol blocked IKK activation by inhibiting one or many of the upstream kinases responsible for IKK activation. It has been shown that TNF-induced IKK activation requires the activation of Akt (42). Our results demonstrate that flavopiridol can indeed suppress the TNF-induced Akt activation. Akt has been shown to induce IKK-{alpha} phosphorylation at threonine 23. Mutation of this amino acid blocks phosphorylation by Akt or TNF and activation of NF-{kappa}B (42). We show that flavopiridol does not affect the binding of NF-{kappa}B protein to the DNA (Fig. 3B) but blocks the ubiquitination of I{kappa}B{alpha} and the acylation of p65. Our results thus show that flavopiridol is inhibiting IKK, which leads to the inhibition of phosphorylation, ubiquitination, and degradation of I{kappa}B{alpha}. It could also explain the inhibition of phosphorylation, acetylation, and nuclear translocation of p65. We also demonstrate that purified IKK is not inhibited by flavopiridol (Fig. 5B), but the activation of IKK is suppressed (Fig. 5A). The activation of IKK is in part dependent on an upstream kinase, Akt, which is inhibited by flavopiridol (Fig. 5C). Thus these results clearly show that suppression of Akt leads to inhibition of IKK activation, which in turn blocks phosphorylation, ubiquitination, and degradation of I{kappa}B{alpha}, suggesting that the IKK is the rate-limiting step. Furthermore, IKK has also been implicated in the p65 phosphorylation (43).

Activation of NF-{kappa}B has been linked with the regulation of the cell cycle (56). Flavopiridol is a potent inhibitor of CDKs (2), and NF-{kappa}B activation has been shown to be regulated by CDKs (57). The CDKs were found to regulate transcriptional activation by NF-{kappa}B through interactions with the coactivator p300. The transcriptional activation domain of RelA (p65) interacted with an amino-terminal region of p300, distinct from a carboxyl-terminal region of p300 required for binding to the cyclin E-CDK 2 complex. The CDK inhibitor p21 or a dominant negative CDK 2, which inhibited p300-associated cyclin E-CDK 2 activity, stimulated NF-{kappa}B-dependent gene expression, which was also enhanced by expression of p300 in the presence of p21. The interaction of NF-{kappa}B and CDKs through the p300 and CBP coactivators provides a mechanism for the coordination of transcriptional activation with cell cycle progression. Besides IKK activation, this may be another mechanism of suppression of NF-{kappa}B by flavopiridol.

Besides activating NF-{kappa}B, TNF is also a potent inducer of apoptosis. NF-{kappa}B activation has been shown to mediate the suppression of apoptosis induced by TNF (58-60). Flavopiridol has been shown to enhance the apoptosis induced by TNF and the TNF-related cytokine TNF-related apoptosis-inducing ligand (17). It is possible that the flavopiridol potentiates the apoptotic effects of TNF and TNF-related apoptosis-inducing ligand through suppression of NF-{kappa}B as described here. Flavopiridol has been shown to down-regulate the expression of anti-apoptotic genes (8, 11, 23). Because these genes are regulated by NF-{kappa}B (27-30), these genes must be down-regulated through inhibition of NF-{kappa}B.

In our study, flavopiridol down-regulated the expression of cyclin D1, COX-2, and MMP-9, all known to be regulated by NF-{kappa}B (31, 32, 51, 52). The down-regulation of cyclin D1 by flavopiridol has been reported previously (24), but the down-regulation of COX-2 and MMP-9 by flavopiridol has not. Both COX-2 and MMP-9 play an important role in angiogenesis and the invasion of tumors. Vascular endothelial growth factor, another growth factor known to mediate angiogenesis, has also been shown to be down-regulated by flavopiridol (25, 26). Because vascular endothelial growth factor is also an NF-{kappa}B-regulated gene (33), it is possible that flavopiridol suppresses vascular endothelial growth factor expression by down-regulating NF-{kappa}B. Besides anti-apoptosis, NF-{kappa}B has been implicated in inflammation and immune regulation (34). Thus these activities are also most likely mediated through the suppression of NF-{kappa}B.

Overall, our results demonstrate that flavopiridol is a potent inhibitor of NF-{kappa}B activation, which may explain its proapoptotic, anti-angiogenic, anti-inflammatory, and immunomodulatory effects.


   FOOTNOTES
 
* This work was supported in part by the Clayton Foundation for Research (to B. B. A.), Department of Defense United States Army Breast Cancer Research Program Grant BC010610 [GenBank] (to B. B. A.), a PO1 Grant CA91844 from the National Institutes of Health on Lung Cancer Chemoprevention (to B. B. A.), and a P50 Head and Neck SPORE Grant from the National Institutes of Health (to B. B. A.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Back

{ddagger} To whom correspondence should be addressed. Tel.: 713-792-3503/6459; Fax: 713-794-1613; E-mail: aggarwal{at}mdanderson.org.

1 The abbreviations used are: CDK, cyclin-dependent kinase; TNF, tumor necrosis factor; TNFR 1, TNF receptor 1; I{kappa}B, inhibitory subunit of NF-{kappa}B; IKK, I{kappa}B{alpha} kinase; NIK, NF-{kappa}B-inducing kinase; TRAF 2, TNF receptor-associated factor-2; TRADD, TNF receptor-associated death domain; EMSA, electrophoretic mobility shift assay; SEAP, secretory alkaline phosphatase; PMA, phorbol myristate acetate; ALLN, N-Ac-Leu-Leu-norleucinal; MEKK 1, mitogen-activated protein kinase/extracellular signal-regulated kinase kinase-1; COX-2, cyclooxygenase-2; MMP-9, matrix metalloprotease-9; TAK 2, TGF{beta}-activated kinase 2. Back



   REFERENCES
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Naik, R. G., Kattige, S. L., Bhat, S. V., Alreja, B., de Sousa, N. J., and Rupp, R. H. (1988) Tetrahedron 44, 2081[CrossRef]
  2. Carlson, B. A., Dubay, M. M., Sausville, E. A., Brizuela, L., and Worland, P. J. (1996) Cancer Res. 56, 2973-2978[Abstract/Free Full Text]
  3. Losiewicz, M. D., Carlson, B. A., Kaur, G., Sausville, E. A., and Worland, P. J. (1994) Biochem. Biophys. Res. Commun. 201, 589-595[CrossRef][Medline] [Order article via Infotrieve]
  4. De Azevedo, W. F., Jr., Mueller-Dieckmann, H. J., Schulze-Gahmen, U., Worland, P. J., Sausville, E., and Kim, S. H. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 2735-2740[Abstract/Free Full Text]
  5. Worland, P. J., Kaur, G., Stetler-Stevenson, M., Sebers, S., Sartor, O., and Sausville, E. A. (1993) Biochem. Pharmacol. 46, 1831-1840[CrossRef][Medline] [Order article via Infotrieve]
  6. Kaur, G., Stetler-Stevenson, M., Sebers, S., Worland, P., Sedlacek, H., Myers, C., Czech, J., Naik, R., and Sausville, E. (1992) J. Natl. Cancer Inst. 84, 1736-1740[Abstract/Free Full Text]
  7. Bible, K. C., and Kaufmann, S. H. (1996) Cancer Res. 56, 4856-4861[Abstract/Free Full Text]
  8. Konig, A., Schwartz, G. K., Mohammad, R. M., Al-Katib, A., and Gabrilove, J. L. (1997) Blood 90, 4307-4312[Abstract/Free Full Text]
  9. Arguello, F., Alexander, M., Sterry, J. A., Tudor, G., Smith, E. M., Kalavar, N. T., Greene, J. F., Jr., Koss, W., Morgan, C. D., Stinson, S. F., Siford, T. J., Alvord, W. G., Klabansky, R. L., and Sausville, E. A. (1998) Blood 91, 2482-2490[Abstract/Free Full Text]
  10. Byrd, J. C., Shinn, C., Waselenko, J. K., Fuchs, E. J., Lehman, T. A., Nguyen, P. L., Flinn, I. W., Diehl, L. F., Sausville, E., and Grever, M. R. (1998) Blood 92, 3804-3816[Abstract/Free Full Text]
  11. Gojo, I., Zhang, B., and Fenton, R. G. (2002) Clin. Cancer Res. 8, 3527-3538[Abstract/Free Full Text]
  12. Patel, V., Senderowicz, A. M., Pinto, D., Jr., Igishi, T., Raffeld, M., Quintanilla-Martinez, L., Ensley, J. F., Sausville, E. A., and Gutkind, J. S. (1998) J. Clin. Investig. 102, 1674-1681[Medline] [Order article via Infotrieve]
  13. Karp, J. E., Ross, D. D., Yang, W., Tidwell, M. L., Wei, Y., Greer, J., Mann, D. L., Nakanishi, T., Wright, J. J., and Colevas, A. D. (2003) Clin. Cancer Res. 9, 307-315[Abstract/Free Full Text]
  14. Senderowicz, A. M., and Sausville, E. A. (2000) J. Natl. Cancer Inst. 92, 376-387[Abstract/Free Full Text]
  15. Shapiro, G. I., Supko, J. G., Patterson, A., Lynch, C., Lucca, J., Zacarola, P. F., Muzikansky, A., Wright, J. J., Lynch, T. J., Jr., and Rollins, B. J. (2001) Clin. Cancer Res. 7, 1590-1599[Abstract/Free Full Text]
  16. Schwartz, G. K., Werner, J. L., Maslak, P., Saltz, L., O'Reilly, E., Keslen, D. P., Inzeo, D., Sugarman, A., Tong, W., and Spriggs, D. (1998) Proc. Am. Soc. Clin. Oncol. 17, 188
  17. Kim, D. M., Koo, S. Y., Jeon, K., Kim, M. H., Lee, J., Hong, C. Y., and Jeong, S. (2003) Cancer Res. 63, 621-626[Abstract/Free Full Text]
  18. Cartee, L., Maggio, S. C., Smith, R., Sankala, H. M., Dent, P., and Grant, S. (2003) Mol. Cancer Ther. 2, 83-93[Abstract/Free Full Text]
  19. Wu, K., Wang, C., D'Amico, M., Lee, R. J., Albanese, C., Pestell, R. G., and Mani, S. (2002) Mol. Cancer Ther. 1, 695-706[Abstract/Free Full Text]
  20. Nahta, R., Iglehart, J. D., Kempkes, B., and Schmidt, E. V. (2002) Cancer Res. 62, 2267-2271[Abstract/Free Full Text]
  21. Bible, K. C., and Kaufmann, S. H. (1997) Cancer Res. 57, 3375-3380[Abstract/Free Full Text]
  22. Kitada, S., Zapata, J. M., Andreeff, M., and Reed, J. C. (2000) Blood 96, 393-397[Abstract/Free Full Text]
  23. Wittmann, S., Bali, P., Donapaty, S., Nimmanapalli, R., Guo, F., Yamaguchi, H., Huang, M., Jove, R., Wang, H. G., and Bhalla, K. (2003) Cancer Res. 63, 93-99[Abstract/Free Full Text]
  24. Carlson, B., Lahusen, T., Singh, S., Loaiza-Perez, A., Worland, P. J., Pestell, R., Albanese, C., Sausville, E. A., and Senderowicz, A. M. (1999) Cancer Res. 59, 4634-4641[Abstract/Free Full Text]
  25. Rapella, A., Negrioli, A., Melillo, G., Pastorino, S., Varesio, L., and Bosco, M. C. (2002) Int. J. Cancer 99, 658-664[CrossRef][Medline] [Order article via Infotrieve]
  26. Melillo, G., Sausville, E. A., Cloud, K., Lahusen, T., Varesio, L., and Senderowicz, A. M. (1999) Cancer Res. 59, 5433-5437[Abstract/Free Full Text]
  27. Wang, C. Y., Mayo, M. W., Korneluk, R. G., Goeddel, D. V., and Baldwin, A. S., Jr. (1998) Science 281, 1680-1683[Abstract/Free Full Text]
  28. Khoshnan, A., Tindell, C., Laux, I., Bae, D., Bennett, B., and Nel, A. E. (2000) J. Immunol. 165, 1743-1754[Abstract/Free Full Text]
  29. Bui, N. T., Livolsi, A., Peyron, J. F., and Prehn, J. H. (2001) J. Cell Biol. 152, 753-764[Abstract/Free Full Text]
  30. Micheau, O., Lens, S., Gaide, O., Alevizopoulos, K., and Tschopp, J. (2001) Mol. Cell. Biol. 21, 5299-5305[Abstract/Free Full Text]
  31. Guttridge, D. C., Albanese, C., Reuther, J. Y., Pestell, R. G., and Baldwin, A. S., Jr. (1999) Mol. Cell. Biol. 19, 5785-5799[Abstract/Free Full Text]
  32. Hinz, M., Krappmann, D., Eichten, A., Heder, A., Scheidereit, C., and Strauss, M. (1999) Mol. Cell. Biol. 19, 2690-2698[Abstract/Free Full Text]
  33. Huang, S., Robinson, J. B., Deguzman, A., Bucana, C. D., and Fidler, I. J. (2000) Cancer Res. 60, 5334-5339[Abstract/Free Full Text]
  34. Baeuerle, P. A., and Baichwal, V. R. (1997) Adv. Immunol. 65, 111-137[Medline] [Order article via Infotrieve]
  35. Chaturvedi, M. M., Mukhopadhyay, A., and Aggarwal, B. B. (2000) Methods Enzymol. 319, 585-602[Medline] [Order article via Infotrieve]
  36. Takada, Y., and Aggarwal, B. B. (2003) J. Biol. Chem. 278, 23390-23397[Abstract/Free Full Text]
  37. Manna, S. K., Mukhopadhyay, A., and Aggarwal, B. B. (2000) J. Immunol. 165, 4927-4934[Abstract/Free Full Text]
  38. Takada, Y., Mukhopadhyay, A., Kundu, G. C., Mahabeleshwar, G. H., Singh, S., and Aggarwal, B. B. (2003) J. Biol. Chem. 278, 24233-24241[Abstract/Free Full Text]
  39. Chaturvedi, M. M., LaPushin, R., and Aggarwal, B. B. (1994) J. Biol. Chem. 269, 14575-14583[Abstract/Free Full Text]
  40. Ghosh, S., and Karin, M. (2002) Cell 109, (suppl.) S81-S96
  41. Vinitsky, A., Michaud, C., Powers, J. C., and Orlowski, M. (1992) Biochemistry 31, 9421-9428[CrossRef][Medline] [Order article via Infotrieve]
  42. Ozes, O. N., Mayo, L. D., Gustin, J. A., Pfeffer, S. R., Pfeffer, L. M., and Donner, D. B. (1999) Nature 401, 82-85[CrossRef][Medline] [Order article via Infotrieve]
  43. Sizemore, N., Lerner, N., Dombrowski, N., Sakurai, H., and Stark, G. R. (2002) J. Biol. Chem. 277, 3863-3869[Abstract/Free Full Text]
  44. Chen, L. F., Fischle, W., Verdin, E., and Greene, W. C. (2001) Science 293, 1653-1657[Abstract/Free Full Text]
  45. Pahl, H. L. (1999) Oncogene 18, 6853-6866[CrossRef][Medline] [Order article via Infotrieve]
  46. Garg, A., and Aggarwal, B. B. (2002) Leukemia (Baltimore) 16, 1053-1068
  47. Anto, R. J., Mukhopadhyay, A., Shishodia, S., Gairola, C. G., and Aggarwal, B. B. (2002) Carcinogenesis 23, 1511-1518[Abstract/Free Full Text]
  48. Nasuhara, Y., Adcock, I. M., Catley, M., Barnes, P. J., and Newton, R. (1999) J. Biol. Chem. 274, 19965-19972[Abstract/Free Full Text]
  49. Simeonidis, S., Stauber, D., Chen, G., Hendrickson, W. A., and Thanos, D. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 49-54[Abstract/Free Full Text]
  50. Hsu, H., Shu, H. B., Pan, M. G., and Goeddel, D. V. (1996) Cell 84, 299-308[CrossRef][Medline] [Order article via Infotrieve]
  51. Yamamoto, K., Arakawa, T., Ueda, N., and Yamamoto, S. (1995) J. Biol. Chem. 270, 31315-31320[Abstract/Free Full Text]
  52. Esteve, P. O., Chicoine, E., Robledo, O., Aoudjit, F., Descoteaux, A., Potworowski, E. F., and St.-Pierre, Y. (2002) J. Biol. Chem. 277, 35150-35155[Abstract/Free Full Text]
  53. Maniatis, T. (1997) Science 278, 818-819[Free Full Text]
  54. Stancovski, I., and Baltimore, D. (1997) Cell 91, 299-302[CrossRef][Medline] [Order article via Infotrieve]
  55. Verma, I. M., Stevenson, J. K., Schwarz, E. M., Van Antwerp, D., and Miyamoto, S. (1995) Genes Dev. 9, 2723-2735[Free Full Text]
  56. Joyce, D., Albanese, C., Steer, J., Fu, M., Bouzahzah, B., and Pestell, R. G. (2001) Cytokine Growth Factor Rev. 12, 73-90[CrossRef][Medline] [Order article via Infotrieve]
  57. Perkins, N. D., Felzien, L. K., Betts, J. C., Leung, K., Beach, D. H., and Nabel, G. J. (1997) Science 275, 523-527[Abstract/Free Full Text]
  58. Van Antwerp, D. J., Martin, S. J., Kafri, T., Green, D. R., and Verma, I. M. (1996) Science 274, 787-789[Abstract/Free Full Text]
  59. Beg, A. A., and Baltimore, D. (1996) Science 274, 782-784[Abstract/Free Full Text]
  60. Wang, C. Y., Mayo, M. W., and Baldwin, A. S., Jr. (1996) Science 274, 784-787[Abstract/Free Full Text]

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 CarcinogenesisHome page
S. Sarfaraz, I. A. Siddiqui, D. N. Syed, F. Afaq, and H. Mukhtar
Guggulsterone modulates MAPK and NF-{kappa}B pathways and inhibits skin tumorigenesis in SENCAR mice
Carcinogenesis, October 1, 2008; 29(10): 2011 - 2018.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
Y. Ge, J. S. Byun, P. De Luca, G. Gueron, I. M. Yabe, S. G. Sadiq-Ali, W. D. Figg, J. Quintero, C. M. Haggerty, Q. Q. Li, et al.
Combinatorial Antileukemic Disruption of Oxidative Homeostasis and Mitochondrial Stability by the Redox Reactive Thalidomide 2-(2,4-Difluoro-phenyl)-4,5,6,7-tetrafluoro-1H-isoindole-1,3(2H)-dione (CPS49) and Flavopiridol
Mol. Pharmacol., September 1, 2008; 74(3): 872 - 883.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
Y. Takada, G. Sethi, B. Sung, and B. B. Aggarwal
Flavopiridol Suppresses Tumor Necrosis Factor-Induced Activation of Activator Protein-1, c-Jun N-Terminal Kinase, p38 Mitogen-Activated Protein Kinase (MAPK), p44/p42 MAPK, and Akt, Inhibits Expression of Antiapoptotic Gene Products, and Enhances Apoptosis through Cytochrome c Release and Caspase Activation in Human Myeloid Cells
Mol. Pharmacol., May 1, 2008; 73(5): 1549 - 1557.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. E. Smith, V. Cimica, S. Chinni, K. Challagulla, S. Mani, and G. V. Kalpana
Rhabdoid Tumor Growth is Inhibited by Flavopiridol
Clin. Cancer Res., January 15, 2008; 14(2): 523 - 532.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
C. Mitchell, M. A. Park, G. Zhang, A. Yacoub, D. T. Curiel, P. B. Fisher, J. D. Roberts, S. Grant, and P. Dent
Extrinsic pathway- and cathepsin-dependent induction of mitochondrial dysfunction are essential for synergistic flavopiridol and vorinostat lethality in breast cancer cells
Mol. Cancer Ther., December 1, 2007; 6(12): 3101 - 3112.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
C. Nicholas, S. Batra, M. A. Vargo, O. H. Voss, M. A. Gavrilin, M. D. Wewers, D. C. Guttridge, E. Grotewold, and A. I. Doseff
Apigenin Blocks Lipopolysaccharide-Induced Lethality In Vivo and Proinflammatory Cytokines Expression by Inactivating NF-{kappa}B through the Suppression of p65 Phosphorylation
J. Immunol., November 15, 2007; 179(10): 7121 - 7127.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
G. Sethi, K. S. Ahn, D. Xia, J. M. Kurie, and B. B. Aggarwal
Targeted Deletion of MKK4 Gene Potentiates TNF-Induced Apoptosis through the Down-Regulation of NF-{kappa}B Activation and NF-{kappa}B-Regulated Antiapoptotic Gene Products
J. Immunol., August 1, 2007; 179(3): 1926 - 1933.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. B. Kunnumakkara, A. S. Nair, K. S. Ahn, M. K. Pandey, Z. Yi, M. Liu, and B. B. Aggarwal
Gossypin, a pentahydroxy glucosyl flavone, inhibits the transforming growth factor beta-activated kinase-1-mediated NF-{kappa}B activation pathway, leading to potentiation of apoptosis, suppression of invasion, and abrogation of osteoclastogenesis
Blood, June 15, 2007; 109(12): 5112 - 5121.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
B. Sung, M. K. Pandey, and B. B. Aggarwal
Fisetin, an Inhibitor of Cyclin-Dependent Kinase 6, Down-Regulates Nuclear Factor-{kappa}B-Regulated Cell Proliferation, Antiapoptotic and Metastatic Gene Products through the Suppression of TAK-1 and Receptor-Interacting Protein-Regulated I{kappa}B{alpha} Kinase Activation
Mol. Pharmacol., June 1, 2007; 71(6): 1703 - 1714.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. K. Manna, R. S. Aggarwal, G. Sethi, B. B. Aggarwal, and G. T. Ramesh
Morin (3,5,7,2',4'-Pentahydroxyflavone) Abolishes Nuclear Factor-{kappa}B Activation Induced by Various Carcinogens and Inflammatory Stimuli, Leading to Suppression of Nuclear Factor-{kappa}B-Regulated Gene Expression and Up-regulation of Apoptosis
Clin. Cancer Res., April 1, 2007; 13(7): 2290 - 2297.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
R. R. Rosato, J. A. Almenara, S. S. Kolla, S. C. Maggio, S. Coe, M. S. Gimenez, P. Dent, and S. Grant
Mechanism and functional role of XIAP and Mcl-1 down-regulation in flavopiridol/vorinostat antileukemic interactions
Mol. Cancer Ther., February 1, 2007; 6(2): 692 - 702.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
A. S. Nair, S. Shishodia, K. S. Ahn, A. B. Kunnumakkara, G. Sethi, and B. B. Aggarwal
Deguelin, an Akt Inhibitor, Suppresses I{kappa}B{alpha} Kinase Activation Leading to Suppression of NF-{kappa}B-Regulated Gene Expression, Potentiation of Apoptosis, and Inhibition of Cellular Invasion
J. Immunol., October 15, 2006; 177(8): 5612 - 5622.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
H. Ichikawa, M. S. Nair, Y. Takada, D.B. A. Sheeja, M.A. S. Kumar, O. V. Oommen, and B. B. Aggarwal
Isodeoxyelephantopin, a Novel Sesquiterpene Lactone, Potentiates Apoptosis, Inhibits Invasion, and Abolishes Osteoclastogenesis through Suppression of Nuclear Factor-{kappa}B (NF-{kappa}B) Activation and NF-{kappa}B-Regulated Gene Expression.
Clin. Cancer Res., October 1, 2006; 12(19): 5910 - 5918.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
G. Sethi, K. S. Ahn, S. K. Sandur, X. Lin, M. M. Chaturvedi, and B. B. Aggarwal
Indirubin Enhances Tumor Necrosis Factor-induced Apoptosis through Modulation of Nuclear Factor-{kappa}B Signaling Pathway
J. Biol. Chem., August 18, 2006; 281(33): 23425 - 23435.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
O. Lopez-Franco, P. Hernandez-Vargas, G. Ortiz-Munoz, G. Sanjuan, Y. Suzuki, L. Ortega, J. Blanco, J. Egido, and C. Gomez-Guerrero
Parthenolide Modulates the NF-{kappa}B-Mediated Inflammatory Responses in Experimental Atherosclerosis
Arterioscler. Thromb. Vasc. Biol., August 1, 2006; 26(8): 1864 - 1870.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
K. S. Ahn, G. Sethi, A. K. Jain, A. K. Jaiswal, and B. B. Aggarwal
Genetic Deletion of NAD(P)H:Quinone Oxidoreductase 1 Abrogates Activation of Nuclear Factor-{kappa}B, I{kappa}B{alpha} Kinase, c-Jun N-terminal Kinase, Akt, p38, and p44/42 Mitogen-activated Protein Kinases and Potentiates Apoptosis
J. Biol. Chem., July 21, 2006; 281(29): 19798 - 19808.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
S. K. Sandur, H. Ichikawa, G. Sethi, K. S. Ahn, and B. B. Aggarwal
Plumbagin (5-Hydroxy-2-methyl-1,4-naphthoquinone) Suppresses NF-{kappa}B Activation and NF-{kappa}B-regulated Gene Products Through Modulation of p65 and I{kappa}B{alpha} Kinase Activation, Leading to Potentiation of Apoptosis Induced by Cytokine and Chemotherapeutic Agents
J. Biol. Chem., June 23, 2006; 281(25): 17023 - 17033.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
E. B. Sambol, G. Ambrosini, R. C. Geha, P. T. Kennealey, P. DeCarolis, R. O'Connor, Y. V. Wu, M. Motwani, J.-H. Chen, G. K. Schwartz, et al.
Flavopiridol Targets c-KIT Transcription and Induces Apoptosis in Gastrointestinal Stromal Tumor Cells
Cancer Res., June 1, 2006; 66(11): 5858 - 5866.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
H. Ichikawa, Y. Takada, S. Shishodia, B. Jayaprakasam, M. G. Nair, and B. B. Aggarwal
Withanolides potentiate apoptosis, inhibit invasion, and abolish osteoclastogenesis through suppression of nuclear factor-{kappa}B (NF-{kappa}B) activation and NF-{kappa}B-regulated gene expression.
Mol. Cancer Ther., June 1, 2006; 5(6): 1434 - 1445.
[Abstract] [Full Text] [PDF]

Home page
 aacredbookHome page
S. Grant
Nuclear Acetylation Targets: NF-{kappa}B and the ROS Connection
Am. Assoc. Cancer Res. Educ. Book, April 1, 2006; 2006(1): 322 - 326.
[Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
Y. Takada, A. Gillenwater, H. Ichikawa, and B. B. Aggarwal
Suberoylanilide Hydroxamic Acid Potentiates Apoptosis, Inhibits Invasion, and Abolishes Osteoclastogenesis by Suppressing Nuclear Factor-{kappa}B Activation
J. Biol. Chem., March 3, 2006; 281(9): 5612 - 5622.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
Y. Takada, H. Ichikawa, V. Badmaev, and B. B. Aggarwal
Acetyl-11-Keto-beta-Boswellic Acid Potentiates Apoptosis, Inhibits Invasion, and Abolishes Osteoclastogenesis by Suppressing NF-{kappa}B and NF-{kappa}B-Regulated Gene Expression.
J. Immunol., March 1, 2006; 176(5): 3127 - 3140.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
G. Dasmahapatra, J. A. Almenara, and S. Grant
Flavopiridol and Histone Deacetylase Inhibitors Promote Mitochondrial Injury and Cell Death in Human Leukemia Cells That Overexpress Bcl-2
Mol. Pharmacol., January 1, 2006; 69(1): 288 - 298.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
Y. Takada, M. Andreeff, and B. B. Aggarwal
Indole-3-carbinol suppresses NF-{kappa}B and I{kappa}B{alpha} kinase activation, causing inhibition of expression of NF-{kappa}B-regulated antiapoptotic and metastatic gene products and enhancement of apoptosis in myeloid and leukemia cells
Blood, July 15, 2005; 106(2): 641 - 649.
[Abstract] [Full Text] [PDF]

Home page
 Neuro OncolHome page
E. W. Newcomb, M. A. Ali, T. Schnee, L. Lan, Y. Lukyanov, M. Fowkes, D. C. Miller, and D. Zagzag
Flavopiridol downregulates hypoxia-mediated hypoxia-inducible factor-1{alpha} expression in human glioma cells by a proteasome-independent pathway: Implications for in vivo therapy
Neuro-oncol, July 1, 2005; 7(3): 225 - 235.
[Abstract] [PDF]

Home page
 J. Immunol.Home page
H. Ichikawa, Y. Takada, A. Murakami, and B. B. Aggarwal
Identification of a Novel Blocker of I{kappa}B{alpha} Kinase That Enhances Cellular Apoptosis and Inhibits Cellular Invasion through Suppression of NF-{kappa}B-Regulated Gene Products
J. Immunol., June 1, 2005; 174(11): 7383 - 7392.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. A. Shah, J. Kortmansky, M. Motwani, M. Drobnjak, M. Gonen, S. Yi, A. Weyerbacher, C. Cordon-Cardo, R. Lefkowitz, B. Brenner, et al.
A Phase I Clinical Trial of the Sequential Combination of Irinotecan Followed by Flavopiridol
Clin. Cancer Res., May 15, 2005; 11(10): 3836 - 3845.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
Y. Takada, Y. Kobayashi, and B. B. Aggarwal
Evodiamine Abolishes Constitutive and Inducible NF-{kappa}B Activation by Inhibiting I{kappa}B{alpha} Kinase Activation, Thereby Suppressing NF-{kappa}B-regulated Antiapoptotic and Metastatic Gene Expression, Up-regulating Apoptosis, and Inhibiting Invasion
J. Biol. Chem., April 29, 2005; 280(17): 17203 - 17212.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
T. Syrovets, J. E. Gschwend, B. Buchele, Y. Laumonnier, W. Zugmaier, F. Genze, and T. Simmet
Inhibition of I{kappa}B Kinase Activity by Acetyl-boswellic Acids Promotes Apoptosis in Androgen-independent PC-3 Prostate Cancer Cells in Vitro and in Vivo
J. Biol. Chem., February 18, 2005; 280(7): 6170 - 6180.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
T. Syrovets, B. Buchele, C. Krauss, Y. Laumonnier, and T. Simmet
Acetyl-Boswellic Acids Inhibit Lipopolysaccharide-Mediated TNF-{alpha} Induction in Monocytes by Direct Interaction with I{kappa}B Kinases
J. Immunol., January 1, 2005; 174(1): 498 - 506.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
Y. Takada and B. B. Aggarwal
Evidence that genetic deletion of the TNF receptor p60 or p80 in macrophages modulates RANKL-induced signaling
Blood, December 15, 2004; 104(13): 4113 - 4121.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
X.-Y. Pei, Y. Dai, and S. Grant
The small-molecule Bcl-2 inhibitor HA14-1 interacts synergistically with flavopiridol to induce mitochondrial injury and apoptosis in human myeloma cells through a free radical-dependent and Jun NH2-terminal kinase-dependent mechanism
Mol. Cancer Ther., December 1, 2004; 3(12): 1513 - 1524.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
N. Gao, Y. Dai, M. Rahmani, P. Dent, and S. Grant
Contribution of Disruption of the Nuclear Factor-{kappa}B Pathway to Induction of Apoptosis in Human Leukemia Cells by Histone Deacetylase Inhibitors and Flavopiridol
Mol. Pharmacol., October 1, 2004; 66(4): 956 - 963.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
Y. Takada, X. Fang, Md. S. Jamaluddin, D. D. Boyd, and B. B. Aggarwal
Genetic Deletion of Glycogen Synthase Kinase-3{beta} Abrogates Activation of I{kappa}B{alpha} Kinase, JNK, Akt, and p44/p42 MAPK but Potentiates Apoptosis Induced by Tumor Necrosis Factor
J. Biol. Chem., September 17, 2004; 279(38): 39541 - 39554.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
S. Grant and P. Dent
Gene profiling and the cyclin-dependent kinase inhibitor flavopiridol: What's in a name?
Mol. Cancer Ther., July 1, 2004; 3(7): 873 - 875.
[Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
Y. Takada, F. R. Khuri, and B. B. Aggarwal
Protein Farnesyltransferase Inhibitor (SCH 66336) Abolishes NF-{kappa}B Activation Induced by Various Carcinogens and Inflammatory Stimuli Leading to Suppression of NF-{kappa}B-regulated Gene Expression and Up-regulation of Apoptosis
J. Biol. Chem., June 18, 2004; 279(25): 26287 - 26299.
[Abstract] [Full Text] [PDF]

Home page
 ScienceHome page
M. E. M. Noble, J. A. Endicott, and L. N. Johnson
Protein Kinase Inhibitors: Insights into Drug Design from Structure
Science, March 19, 2004; 303(5665): 1800 - 1805.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
279/6/4750    most recent
M304546200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Takada, Y.
Right arrow Articles by Aggarwal, B. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Takada, Y.
Right arrow Articles by Aggarwal, B. B.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2004 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement